论文部分内容阅读
目的:研究生存素(Survivin)、K-ras蛋白表达与非小细胞肺癌(NSCLC)放疗敏感性的关系,为NSCLC放疗敏感性的预测提供依据。方法:采用免疫组化染色法检测62例晚期NSCLC的Sur-vivin、K-ras蛋白的表达,所有病例均给予总量为60～70Gy的三维适形放疗,按照实体瘤近期疗效标准(RECIST标准)进行疗效评价,分析Survivin、K-ras蛋白的表达与放疗敏感性的关系。结果:Sur-vivin蛋白(-)、(+)、(++)和(+++)患者经过放疗后,获得近期治疗有效率分别为94.1%、92.9%、80.0%和68.8%,组间比较差异有统计学意义,χ2=4.578,P=0.032;K-ras蛋白(-)、(+)、(++)和(+++)患者经过放疗后,获得近期治疗有效率分别为93.8%、89.5%、81.3%和63.6%,组间比较差异有统计学意义,χ2=4.439,P=0.035。结论:Survivin、K-ras蛋白表达与NSCLC患者的近期放疗疗效呈明显的负相关,检测这两种蛋白的表达有望成为预测NSCLC放疗敏感性的指标。
Objective: To investigate the relationship between the expression of Survivin and K-ras and the radiosensitivity of non-small cell lung cancer (NSCLC), and to provide the basis for the prediction of radiosensitivity of NSCLC. Methods: The expressions of Sur-vivin and K-ras in 62 cases of advanced non-small cell lung cancer (NSCLC) were detected by immunohistochemical staining. All patients were given 3D conformal radiotherapy (60-70 Gy). According to the RECIST standard ) To evaluate the efficacy of Survivin, K-ras protein expression and the relationship between radiosensitivity. RESULTS: The immediate treatment response rates of Survivin (-), (+), (++) and (+++) patients after radiotherapy were 94.1%, 92.9%, 80.0% and 68.8% The difference was statistically significant (χ2 = 4.578, P = 0.032). The effective rates of short-term treatment after K-ras protein (-), (+), (++) and (+++) were 93.8 %, 89.5%, 81.3% and 63.6% respectively. The difference between the two groups was statistically significant (χ2 = 4.439, P = 0.035). CONCLUSIONS: The expressions of Survivin and K-ras proteins are significantly negatively correlated with the recent radiotherapy efficacy in patients with NSCLC. Detecting the expression of these two proteins may be an index to predict the radiosensitivity of NSCLC.